This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Non-falciparum Malaria

This study has been completed.
Information provided by (Responsible Party):
Michael Ramharter, Albert Schweitzer Hospital Identifier:
First received: July 14, 2008
Last updated: February 16, 2012
Last verified: February 2012
Patients with non-falciparum infection will be given artemether-lumefantrine for three days and will be followed up for 28 days. Besides efficacy and safety evaluations a substudy on immunology will be performed.

Condition Intervention
Acute Non-falciparum Malaria Drug: artemether-lumefantrine

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon

Resource links provided by NLM:

Further study details as provided by Michael Ramharter, Albert Schweitzer Hospital:

Primary Outcome Measures:
  • Parasitological cure rate on day 28 [ Time Frame: D28 ]

Secondary Outcome Measures:
  • Frequency and severity of drug related adverse events [ Time Frame: D28 ]

Enrollment: 40
Study Start Date: July 2008
Study Completion Date: February 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: artemether-lumefantrine
Standard artemether-lumefantrine treatment


Ages Eligible for Study:   6 Months to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients between the age of 6 months and 60 years and with a minimum of 5kg bodyweight
  • Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed infection with P.falciparum with parasite density > 50-200000/μl of blood
  • Written informed consent

Exclusion Criteria:

  • Patients with presence of other clinical conditions requiring hospitalization
  • Presence of other febrile conditions
  • Presence of significant anemia, defined by hemoglobin < 7g/dl
  • Known history of hypersensitivity,allergic or adverse reactions to artemether or lumefantrine
  • Intake of any antimalarial or antibiotics with known antimalarial activity in the preceding 2 weeks
  • Pregnant and breast feeding females
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00725777

Medical Research Unit of the Albert Schweitzer Hospital
Lambaréné, Moyen Ogooue, Gabon, BP 118
Sponsors and Collaborators
Albert Schweitzer Hospital
Principal Investigator: Sabine Bélard, MD Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Michael Ramharter, Ass. Prof. PD, Albert Schweitzer Hospital Identifier: NCT00725777     History of Changes
Other Study ID Numbers: IDC-08-01
Study First Received: July 14, 2008
Last Updated: February 16, 2012

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Artemether-lumefantrine combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antifungal Agents
Antiplatyhelmintic Agents
Anthelmintics processed this record on September 21, 2017